# Ambalal Sarabhai Enterprises (NSE: AMBALALSA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/AMBALALSA · Pivot · prices to 21 Oct 2026

Ambalal Sarabhai Enterprises (NSE: AMBALALSA) closed at ₹37.05 on 21 Oct 2026, down 2.44% on the day. With a market capitalisation of ₹291 Cr, it ranks 2072nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 16.4× trailing earnings, against a return on equity of 11.2% in FY26. Its 52-week range is ₹30.15 (23 Jul 2026) to ₹49.98 (10 Aug 2026); the last close is 25.9% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹65 Cr (+1.0% year on year) and net profit ₹6 Cr, on a consolidated basis. Promoters held 31.36% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹37.05 |
| Market cap | ₹291 Cr |
| P/E (trailing) | 16.4 |
| ROE | 11.2% (FY26) |
| ROCE | 12.6% (FY26) |
| Debt to equity | 0.33 |
| 52-week high | ₹49.98 (10 Aug 2026) |
| 52-week low | ₹30.15 (23 Jul 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹65 Cr | +1.0% | ₹6 Cr | — | ₹0.85 |
| Q3 FY26 | ₹52 Cr | +13.1% | ₹3 Cr | +66.3% | ₹0.40 |
| Q2 FY26 | ₹44 Cr | −0.6% | −₹0 Cr | −124.7% | −₹0.07 |
| Q1 FY26 | ₹40 Cr | −0.9% | ₹8 Cr | +1,060.6% | ₹1.07 |
| Q4 FY25 | ₹65 Cr | +19.2% | −₹0 Cr | −101.5% | −₹0.04 |
| Q3 FY25 | ₹46 Cr | +6.6% | ₹2 Cr | +94.4% | ₹0.29 |
| Q2 FY25 | ₹45 Cr | +11.7% | ₹2 Cr | +46.9% | ₹0.34 |
| Q1 FY25 | ₹41 Cr | +12.7% | ₹1 Cr | — | ₹0.05 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹196 Cr | ₹4 Cr |
| FY24 | ₹174 Cr | ₹8 Cr |
| FY23 | ₹170 Cr | ₹12 Cr |
| FY22 | ₹197 Cr | ₹41 Cr |
| FY21 | ₹164 Cr | ₹20 Cr |
| FY20 | ₹134 Cr | ₹15 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 31.36%
- Domestic institutions: 0.01%
- Non-institutions: 68.64%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Lyka Labs](https://app.pivotnow.in/stock/LYKALABS) | ₹86.04 | ₹311 Cr | — | — |
| [Nureca](https://app.pivotnow.in/stock/NURECA) | ₹319.00 | ₹304 Cr | 150.5 | — |
| [Bijoy Hans](https://app.pivotnow.in/stock/BIJHANS) | — | ₹292 Cr | — | — |
| [Astonea Labs](https://app.pivotnow.in/stock/ASTONEALAB) | — | ₹281 Cr | — | — |
| [Espire Hospital](https://app.pivotnow.in/stock/ESPIRE) | — | ₹274 Cr | — | — |
| [Zenotech Labs](https://app.pivotnow.in/stock/ZENOTECH) | — | ₹270 Cr | — | — |

## Questions and answers

### What is the share price of Ambalal Sarabhai Enterprises today?

Ambalal Sarabhai Enterprises (NSE: AMBALALSA) last closed at ₹37.05 on 21 Oct 2026. Its 52-week high is ₹49.98 and its 52-week low is ₹30.15.

### What is the market cap of Ambalal Sarabhai Enterprises?

Ambalal Sarabhai Enterprises' market capitalisation is ₹291 Cr (₹291 Cr) at the 21 Oct 2026 close, ranking 2072nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Ambalal Sarabhai Enterprises?

Ambalal Sarabhai Enterprises trades at a trailing P/E of 16.4.

### What is the ROE and ROCE of Ambalal Sarabhai Enterprises?

Return on equity was 11.2% in FY26 and return on capital employed was 12.6% in FY26 (consolidated figures).

### Is Ambalal Sarabhai Enterprises a debt-free company?

No. Ambalal Sarabhai Enterprises' debt-to-equity ratio was 0.33 in FY26, with total debt of ₹18 Cr.

### What were Ambalal Sarabhai Enterprises' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Ambalal Sarabhai Enterprises reported revenue of ₹65 Cr, +1.0% year on year, and net profit of ₹6 Cr.

### What is the shareholding pattern of Ambalal Sarabhai Enterprises?

As of 30 Jun 2026: promoters 31.36%, domestic institutions 0.01%, non-institutions 68.64%.

### Who are Ambalal Sarabhai Enterprises' competitors?

The listed Pharma & Healthcare companies closest to Ambalal Sarabhai Enterprises by market cap are Lyka Labs, Nureca, Bijoy Hans, Astonea Labs, Espire Hospital and Zenotech Labs.

### Is Ambalal Sarabhai Enterprises a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Ambalal Sarabhai Enterprises' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AMBALALSA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.